Clover Biopharmaceuticals Ltd. · HKEX:2197

Clover Biopharmaceuticals — Investor Presentation (February 2022)

30 slides from Clover Biopharmaceuticals's investor presentation, February 2022

  1. Slide 1: Corporate Presentation

    Corporate Presentation February 2022

  2. Slide 2: Disclaimer

    Disclaimer This presentation contains certain forward-looking statements and information relating to us and our subsidiaries that are based on the beliefs of our management as well as assumptions made by and information currently available to our management. When used, the words "aim," "anticipate,"

  3. Slide 3: Corporate Overview

    Corporate Overview 3

  4. Slide 4: Clover is a Global Innovative Biotechnology Company

    Clover is a Global Innovative Biotechnology Company that Aspires to Empower Humanity with a Healthier Future Through Transformative Science -- Corporate Snapshot -- -- SCB-2019 (CpG 1018/Alum): Differentiated COVID-19 Vaccine Candidate -- Validated Trimer-Tag™ Technology Platform Attractive Product

  5. Slide 5: 2021 Was a Transformational Year for Clover

    2021 Was a Transformational Year for Clover Financings Lead Program Lead Program (SCB-2019) (SCB-2019) Commercial Commercial Readiness Readiness Team Recruitment Team Recruitment >US$850 Million Successful Global Signed APA Doubled Headcount; Cash Received Phase 2/3 Trial Up to 414 Million Doses 800

  6. Slide 6: Global Footprint: Business & Leadership Without Borders

    Global Footprint: Business & Leadership Without Borders Integrated R&D, Manufacturing & Global Clinical Development Capabilities 850+ FTEs (in 16 Countries) 5 Corporate Offices 2 Manufacturing Facilities 3 R&D Centers Europe Chengdu Corporate R&D 20+ FTEs Office Center (Clinical, PM, Ops, Tech Ops)

  7. Slide 7: Diverse Global Leadership Team with Proven Expertise

    Diverse Global Leadership Team with Proven Expertise CEO Founders Joshua Peng Xiaodong Liang Liang, PhD Wang, PhD Chief Executive Officer (CEO) & Founder, Chairman of the Board Non-executive Director Executive Director of the Board & Chief Scientific Officer R&D | Tech Ops Leaders Corporate Leaders

  8. Slide 8: Vaccine Scientific Advisory Board (SAB)

    Vaccine Scientific Advisory Board (SAB) Industry-leading advisors across a broad range of expertise | Advise and guide overall global COVID-19 vaccine development strategy SAB Chairman SAB Members Ralf Clemens Kaia Agarwal Donna Ambrosino MD Sue Ann Costa Clemens Pierre Desmons PhD MD/PhD Chairman o

  9. Slide 9: Trimer-Tag Technology Platform

    Trimer-TagTM Technology Platform  Platform for development of protein-based vaccines and immuno-oncology therapies based on naturally trimerization-dependent targets  Only trimerization technology platform globally for producing recombinant covalently-trimerized fusion proteins utilizing a human-d

  10. Slide 10: In-House R&D Capabilities

    In-House R&D Capabilities Expanding R&D Capabilities in 2022 to Accelerate Development of New Pipeline Products Current Planned in 2022 Chengdu Shanghai Cambridge (UK) Antibody Innovation R&D Center R&D Center Center ~3,300 sqm R&D Center to Support R&D of 25,000+ sqm R&D Center to Support R&D ~500

  11. Slide 11: Strong Commercial Manufacturing Capabilities

    Strong Commercial Manufacturing Capabilities Commercial Manufacturing Infrastructure Established | Building a Global CDMO Network In-house Commercial Manufacturing Facility (Changxing, Zhejiang Province)  4 x 2,000L bioreactor capacity and commercial-scale fill-finish lines installed & qualified 

  12. Slide 12: Robust Pipeline of Innovative Vaccine & Oncology Candidates

    Robust Pipeline of Innovative Vaccine & Oncology Candidates Commercial-Stage COVID-19 Vaccine & Multiple Clinical-Stage Candidates Expected in 2022 Assets Product Candidate Target Indication Discovery Preclinical IND/CTA Phase I Phase II Phase III BLA Future Milestones* Mid-2022 - Regulatory submiss

  13. Slide 13: COVID-19 Vaccine

    COVID-19 Vaccine SCB-2019 (CpG 1018/Alum) 13

  14. Slide 14: Clover's COVID-19 Vaccine Candidate: SCB-2019 (CpG 1018/Alum)

    Clover’s COVID-19 Vaccine Candidate: SCB-2019 (CpG 1018/Alum) -- SCB-2019 (CpG 1018/Alum) Vaccine Design -- SCB-2019 Antigen Structure S1 Prefusion Spike  Adjuvanted Protein-Based COVID-19 Vaccine Candidate: SCB-2019 antigen (30 (S) Protein of µg/dose) in combination with CpG 1018 adjuvant and alum

  15. Slide 15: SCB-2019 (CpG 1018/Alum) Development Status

    SCB-2019 (CpG 1018/Alum) Development Status  Primary Vaccination: Positive Ph 2/3 efficacy & safety established in adults & elderly; data in adolescents & pediatrics in 2022  Universal Booster: Positive initial booster data; multiple data readouts in Q2-2022 & to be included in regulatory submissi

  16. Slide 16: Key Takeaways from Global Phase 2/3 Trial

    Primary Vaccination: Key Takeaways from Global Phase 2/3 Trial Established Efficacy of SCB-2019 (CpG 1018/Alum) Against COVID-19 with a Favorable Safety Profile Study Snapshot Primary & Secondary Efficacy Endpoints Successfully Met <6 From enrollment initiation until Months final efficacy data announc

  17. Slide 17: Attractive & Differentiated Product Profile for SCB-2019

    Primary Vaccination: Attractive & Differentiated Product Profile for SCB-2019 Observed  High Efficacy Against COVID-19  Favorable Safety Profile Efficacy is Comparable to Top-Tier mRNA Vaccine Low Rates of Adverse Events Observed Vaccine Efficacy / Effectiveness Against Delta Variant (1) Any Syste

  18. Slide 18: Universal COVID-19 Booster Development Plan

    Universal Booster: Universal COVID-19 Booster Development Plan  Booster Market Demand: Global rollout of booster doses ongoing & accelerated by (A) continued emergence of new variants with increased immune escape including Omicron and (B) waning immunity from prior vaccination and/or infection  Un

  19. Slide 19: Accumulating Strong Universal COVID-19 Booster Data

    Universal Booster: Accumulating Strong Universal COVID-19 Booster Data  Rapid & Strong Booster Immune Responses Observed (in individuals with previous SARS-CoV-2 infection or vaccinated with AstraZeneca vaccine)  SCB-2019 (CpG 1018/Alum) post-booster neutralizing antibodies observed at levels expe

  20. Slide 20: Global Approach for Regulatory Approval

    Global Approach for Regulatory Approval  Submitting conditional regulatory approval applications to the NMPA, EMA, and WHO; process for rolling submissions ongoing  Regulatory submissions expected to include available booster data and are anticipated to be completed in mid-2022 for the China NMPA

  21. Slide 21: Promoting Fair and Equitable COVID-19 Vaccines to Those in Need

    Promoting Fair and Equitable COVID-19 Vaccines to Those in Need Clover Proudly Supports Fair & Equitable Access of SCB-2019 (CpG 1018/Alum) Vaccination Rates Remain Low in LMICs… COVID-19 Vaccination Rates(1) (as of 12-FEB 2022) High Income Countries ~73% Lower Middle Income Countries ~43% Low Incom

  22. Slide 22: Strong Global Demand Persists for SCB-2019

    Strong Global Demand Persists for SCB-2019 as a Primary & Booster Vaccination  7.5 Billion+ Dose Demand in Clover’s initial primary markets (China and LMIC*) across both primary vaccination and booster (3rd dose) settings; continued boosting and/or emergence of new variants to drive further increas

  23. Slide 23: Next-Generation COVID-19 Vaccine Strategy

    Next-Generation COVID-19 Vaccine Strategy Clover To Utilize  Validated Trimer-TagTM Platform for Next-Gen COVID-19 Vaccine Development Variant-Adapted COVID-19 Vaccine Candidates Produced: Clover has produced and is evaluating multiple variant-adapted COVID- Trimer-TagTM Technology 19 vaccine candi

  24. Slide 24: COVID-19 Vaccine Development Strategy & Lifecycle Plan

    COVID-19 Vaccine Development Strategy & Lifecyle Plan  After initial launch & expanded opportunity development for SCB-2019 (CpG 1018/Alum), we believe we are positioned to have the Annual COVID-19 Booster-of-Choice for the potential endemic vaccination market globally  We also plan to develop Com

  25. Slide 25: Oncology

    Oncology SCB-313 (TRAIL-Trimer) 25

  26. Slide 26: SCB-313 is a TRAIL-Trimer Fusion Protein for Intracavitary Malignancies

    SCB-313 is a TRAIL-Trimer Fusion Protein for Intracavitary Malignancies  SCB-313 is potentially a first-in-class TRAIL-based treatment for Intracavitary Malignancies (Malignant Ascites, Malignant Pleural Effusions, and Peritoneal Carcinomatosis)  Natural, high potency for inducing  Strong Bioacti

  27. Slide 27: Overview of Intracavitary Malignancies

    Overview of Intracavitary Malignancies  No Targeted Medicines are currently available globally for the treatment of MA, MPE and PC indications  Large Global incidence of intracavitary malignancies, reaching 2.5 million patients in 2019 and is estimated to grow to 3.0 million by 2030  SCB-313 is t

  28. Slide 28: Positive SCB-313 Phase 1 Trial Interim Results for Malignant Ascites

    Positive SCB-313 (TRAIL-Trimer) Phase 1 Trial Interim Results for Malignant Ascites  Efficacy Signals Observed  Acceptable Safety Profile Demonstrated Rapid & Durable Decrease in Ascites Flow Rate (1) No Significant Safety Concerns Identified 2000 Adverse Events per Preferred Term (PT) (2) Support

  29. Slide 29: Clover is Focused on Transformative Growth in 2022 & Beyond

    Clover is Focused on Transformative Growth in 2022 & Beyond Goal to Become a Global, Commercial Stage Company in 2022, with a Compelling Innovative Pipeline of Vaccines & Oncology Therapies Key Upcoming Milestones  Additional Universal Booster Clinical Data:  AstraZeneca Viral Vector Vaccine addit

  30. Slide 30: Thank You!

    Q. 24Ra wl id Beretocharnacestcl we

Clover Biopharmaceuticals — Investor Presentation (February 2022) on 6ix